nach oben

Tumor Biology

Erschienen in:

29.09.2015 | Original Article

Antimetastatic effect of fluvastatin on breast and hepatocellular carcinoma cells in relation to SGK1 and NDRG1 genes

verfasst von: Osman Salis, Ali Okuyucu, Abdulkerim Bedir, Ufuk Gör, Canan Kulcu, Eser Yenen, Nermin Kılıç

Erschienen in: Tumor Biology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Metastasis occurs due to migration of the cells from primary tumor toward other tissues by gaining invasive properties. Since metastatic invasion shows a strong resistance against conventional cancer treatments, the studies on this issue have been focused. Within this context, inhibition of migration and determination of the relationships at the gene level will contribute to treatment of metastatic cancer cases. We have aimed to demonstrate the impact of TGF-β1 and fluvastatin on human breast cancer (MCF-7) and human hepatocellular carcinoma (Hep3B) cell cultures via Real-Time Cell Analyzer (RTCA) and to test the expression levels of some genes (NDRG1, SGK1, TWIST1, AMPKA2) and to compare their gene expression levels according to RTCA results. Both of cell series were applied TGF-β₁ and combinations of TGF-β₁/fluvastatin. Primer and probes were synthesized using Universal Probe Library (UPL, Roche) software, and expression levels of genes were tested via qPCR using the device LightCycler 480 II (Roche). Consequently, fluvastatin dose-dependently inhibited migration induced by TGF-β1 in both groups. This inhibition was accompanied by low level of SGK1 messenger RNA (mRNA) and high levels of NDRG1 and AMPKA2 mRNA. Thus, we conclude that fluvastatin plays an important role in reducing resistance to chemotherapeutics and preventing metastasis.

Yilmaz M, Christofori G. Mechanisms of motility in metastasizing cells. Mol Cancer Res. 2010;8:629–42.CrossRefPubMed

Kalluri R. Weinberg RA The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–8.CrossRefPubMedPubMedCentral

Wendt MK, Allington TM, Schiemann WP. Mechanisms of the epithelial-mesenchymal transition by TGF-β. Future Oncol. 2009;5(8):1145–68.CrossRefPubMedPubMedCentral

Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest. 2010;120(1):41–50.CrossRefPubMedPubMedCentral

Le NT, Richardson DR. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood. 2004;104:2967–75.CrossRefPubMed

Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell. 2009;139(5):871–90.CrossRefPubMed

Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818–29.CrossRefPubMed

Ikushima H, Miyazono K. TGFb signalling: a complex web in cancer progression. Nat Rev Cancer. 2010;10:415–24.CrossRefPubMed

Xu J, Lamouille S, Derynck R. TGF-b-induced epithelial to mesenchymal transition. Cell Res. 2009;19:156–72.CrossRefPubMedPubMedCentral

10.

Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 2006;25(3):435–57.CrossRefPubMed

11.

Bellam N et al. TGF-b signaling alterations and colon cancer. Cancer Treat Res. 2010;155:85–103.CrossRefPubMed

12.

de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst. 2000;92(17):1388–402.CrossRefPubMed

13.

Derynck R, Akhurst RJ. Balmain A TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001;29(2):117–29.CrossRefPubMed

14.

Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.CrossRefPubMedPubMedCentral

15.

Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition ofbreast tumor heterogeneity. Cancer Cell. 2007;11(3):259–73.CrossRefPubMed

16.

Kato S, Smalley S, Sadarangani A, Chen-Lin K, Oliva B, Branes J, et al. Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med. 2010;14:1180–93.PubMed

17.

Barbie T-H, Sandra O, Karlan BY, Andrew J. Li Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells. Gynecol Oncol. 2010;119:549–56.CrossRef

18.

Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16:508–19.CrossRefPubMed

19.

Cohen AW, Schubert W, Brasaemle DL, Scherer PE, Lisanti MP. Caveolin-1 expression is essential for proper nonshivering thermogenesis in brown adipose tissue. Diabetes. 2005;54(3):679–86.CrossRefPubMed

20.

Lang F, Strutz-Seebohm N, Seebohm G, Lang U. Significance of SGK1 in the regulation of neuronal disease. J Physiol. 2010;588(18):3349–54.CrossRefPubMedPubMedCentral

21.

Lang F, Shumilina E. Regulation of ion channels by the serum- and glucocorticoid-inducible kinase SGK1. FASEB J. 2013;27(1):3–12.CrossRefPubMed

22.

Lang F, Artunc F, Vallon V. The physiological impact of the serum and glucocorticoidinducible kinase SGK1. Curr Opin Nephrol Hypertens. 2009;18:439–48.CrossRefPubMedPubMedCentral

23.

Salis O, Bedir A, Gulten S, Okuyucu A, Kulcu C, Alacam H. Cytotoxic Effect of Fluvastatin on MCF-7 Cells Possibly Through a Reduction of the mRNA Expression Levels of SGK1 and CAV1. Cancer Biother Radiopharm. 2014;29(9):368–75.CrossRefPubMed

24.

Thomas P, Ellen TP, Ke Q, Zhang P. () NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states. Carcinogenesis. 2008;29:2–8.

25.

Guan RJ, Ford HL, Fu Y, Li Y, Shaw LM, Pardee AB. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res. 2000;60:749–55.PubMed

26.

Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, Miura K, et al. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res. 2003;63:1731–6.PubMed

27.

Sun B, Chu D, Li W, Chu X, Li Y, Wei D, et al. Decreased expression of NDRG1 in glioma is related to tumor progression and survival of patients. J Neurooncol. 2009;94:213–9.CrossRefPubMed

28.

Chua MS, Sun H, Cheung ST, Mason V, Higgins J, Ross DT, et al. Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma. Mod Pathol. 2006;20:76–83.CrossRefPubMed

29.

Cangul H. Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet. 2004;5:27.CrossRefPubMedPubMedCentral

30.

Salis O, Bedir A, Kilinc V, Alacam H, Gulten S, Okuyucu A. The anticancer effects of desferrioxamine on human breast adenocarcinoma and hepatocellular carcinoma cells. Cancer Biomark. 2014;14(6):419–26.PubMed

31.

Zang M, Zuccollo A, Hou X, Nagata D, Walsh K, Herscovitz H, et al. ”AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem. 2004;279:47898–905.CrossRefPubMed

32.

Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol. 1999;277:1–10.

33.

Chen Y, Doebber T, Hirshman MF, Goodyear LJ, Fenyk-Melody J, Fujii N, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–74.CrossRefPubMedPubMedCentral

34.

Mironchik Y, Winnard Jr PT, Vesuna F, Kato Y, Wildes F, Pathak AP, et al. Twist over expression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res. 2005;65(23):10801–9.CrossRefPubMed

35.

Zeisberg M, Neilson EG. Biomarkers for epithelialmesenchymal transitions. J Clin Invest. 2009;119:1429–37.CrossRefPubMedPubMedCentral

36.

Schoenebeck B, Bader XR, Schmitz B, Lubbert H, Stichel C. Sgk1, a cell survival response in neurodegenerative diseases. Mol Cell Neurosci. 2005;30(2):249–64.CrossRefPubMed

37.

Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N, Vallon V. (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiol Rev. 2006;86:1151–78.CrossRefPubMed

38.

Matsuzaki K, Kitano C, Murata M, Sekimoto G, Yoshida K, Uemura Y, et al. Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-beta signal in later stages of human colorectal cancer. Cancer Res. 2009;69:5321–30.CrossRefPubMed

39.

Hoppe S, Bierhoff H, Cado I, Weber A, Tiebe M, Grummt I, et al. AMP-activated protein kinase adapts rRNA synthesis to cellular energy supply. Proc Natl Acad Sci U S A. 2009;106:17781–6.CrossRefPubMedPubMedCentral

40.

Hardie DG, Alessi DR. LKB1 and AMPK and the cancer-metabolismlink-ten years after. BMC Biol. 2013;15:11–36.

Titel: Antimetastatic effect of fluvastatin on breast and hepatocellular carcinoma cells in relation to SGK1 and NDRG1 genes
verfasst von: Osman Salis
Ali Okuyucu
Abdulkerim Bedir
Ufuk Gör
Canan Kulcu
Eser Yenen
Nermin Kılıç
Publikationsdatum: 29.09.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 3/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4119-2

Springer Medizin

Antimetastatic effect of fluvastatin on breast and hepatocellular carcinoma cells in relation to SGK1 and NDRG1 genes

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Long non-coding RNAs: emerging players in osteosarcoma

Clinical influence of cancer stem cells on residual disease after preoperative chemoradiotherapy for rectal cancer

The role of MALAT1/miR-1/slug axis on radioresistance in nasopharyngeal carcinoma

The plasma lncRNA acting as fingerprint in non-small-cell lung cancer

3-Bromopyruvate inhibits cell proliferation and induces apoptosis in CD133+ population in human glioma

Radiofrequency ablation-increased CXCL10 is associated with earlier recurrence of hepatocellular carcinoma by promoting stemness

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie